Immune checkpoint inhibitors in pancreatic cancer / 中华内分泌外科杂志

ABSTRACT

The comprehensive and multiple disciplinary team therapeutic strategies of pancreatic cancer have been accepted as a consensus. Immune checkpoint inhibitors have made great breakthroughs in the treatment of various solid tumors. However, immune checkpoint inhibitors failed to elicit efficacy in patients with pancreatic cancer and how to overcome the immunosuppressive tumor microenvironment may be the crucial event. Combination regimens of immune checkpoint inhibitors with chemotherapy, radiotherapy, and molecular targeted therapy have been underway, but the sample size of the clinical trial was still limited. Considering the current research status and progress of pancreatic cancer, this article further discusses the practical problems of immune checkpoint inhibitors and makes objective evaluation of its value.